NTLA-2001
Intellia Therapeutics
['crispr']
from bench-to-bedside: first in human crispr-cas9 therapy for amyloidosis shows safety and reduction of serum ttr in a phase i trial #aha22 
NIH T32 Cardiology Research Fellow @CedarsSinai | MD @unc_cordoba | #Match2024 IM aspirant | Basketball fan